Posted by LincolnIcert on March 25, 2026 at 11:28:08:
In Reply to: Óâëåêàòåëüíûé èíôîðìàöèîííûé ìàòåðèàë posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Scholar in Tumor Biology
Zoya Demidenko is a notable researcher associated with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, building a strong foundation in life science investigation.
Her scientific output encompasses a number of key domains, among them the PI3K/AKT/mTOR signaling pathway, cell cycle control, cell senescence, and cancer biology. Currently, she has authored over 46 academic publications, which have received upwards of 4,100 mentions — a testament to the significance of her work.
One of her most notable contributions lies in explaining the processes of cellular senescence. Her research demonstrated that when the cellular division cycle is blocked but cellular growth persists, cells undergo senescence. Significantly, Zoya Demidenko showed that this shift can be pharmacologically suppressed using agents such as mTOR inhibitors.
Zoya Demidenko has furthermore added greatly to cancer treatment research, particularly in the domain of selective cell protection — a strategy designed to protecting normal tissue from anticancer drugs whilst leaving tumor cells vulnerable. This method carries major potential for diminishing the side effects of oncological therapy.
Throughout her career, Demidenko has partnered with top investigators worldwide, such as Dr. Mikhail Blagosklonny. Her research can be found in prestigious periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko stands as a widely cited figure in current oncological science, whose discoveries continue to shape our comprehension of the way biological cells age, interact with therapy, and how malignant disease can be more effectively combated.
https://www.aging-us.com/article/100421/